Table 1.
Baseline Characteristics among 65,788 Patients with Systemic Lupus Erythematosus (SLE) enrolled in Medicaid in the 29 most populated U.S. States, 2000–2010
| White | Black | Hispanic | Asian | American Indian/Alaska Native | |
|---|---|---|---|---|---|
| Total number of patients (N, %) | 25,204 (38.31) | 27,470 (41.76) | 10,562 (16.05) | 1,827 (2.78) | 725 (1.10) |
| Female (N, %) | 23,401 (92.85) | 25,643 (93.35) | 9,846 (93.22) | 1,663 (91.02) | 668 (92.14) |
| Age, years (Mean, SD) | 42.7 (11.98) | 39.70 (11.79) | 39.24 (12.30) | 39.12 (12.72) | 41.9 (11.83) |
| Residential Region (N, %) | |||||
| Midwest | 6,238 (24.75) | 6,060 (22.06) | 701 (6.64) | 142 (7.77) | 89 (12.28) |
| Northeast | 5,151 (20.44) | 4.704 (17.12) | 2,848 (26.96) | 440 (24.08) | 74 (10.21) |
| South | 8,874 (35.21) | 14,126 (51.42) | 2,555 (24.19) | 197 (10.78) | 271 (37.38) |
| West | 4,941 (19.60) | 2,580 (9.39) | 4,458 (42.21) | 1,048 (57.36) | 291 (40.14) |
| Comorbidities (N, %)* | |||||
| Previous Angina | 1,203 (4.77) | 1,122 (4.08) | 398 (3.77) | 47 (2.57) | 15 (2.07) |
| Previous CABG | 88 (0.35) | 85 (0.31) | 31 (0.29) | -- | -- |
| Previous CVA | 1,525 (6.05) | 1,668 (6.07) | 414 (3.92) | 63 (3.45) | 37 (5.10) |
| Coronary atherosclerosis | 2,056 (8.16) | 1,824 (6.64) | 391 (5.81) | 80 (4.38) | 40 (5.52) |
| Previous MI | 716 (2.84) | 742 (2.70) | 157 (1.49) | 34 (1.86) | 25 (3.45) |
| Previous PCI | 211 (0.84) | 160 (0.58) | 49 (0.46) | -- | -- |
| Diabetes mellitus | 3,748 (14.87) | 4,229 (15.39) | 1,566 (14.83) | 203 (11.11) | 141 (19.45) |
| Heart failure | 1,849 (7.34) | 2,988 (10.88) | 644 (6.10) | 133 (7.28) | 44 (6.07) |
| Hypertension | 8,658 (34.35) | 13,309 (48.45) | 3,444 (32.61) | 569 (31.14) | 236 (32.55) |
| Hyperlipidemia | 4,241 (16.83) | 3,102 (11.29) | 1,498 (14.18) | 252 (13.79) | 84 (11.59) |
| Obesity | 1,618 (6.42) | 1,742 (6.34) | 556 (5.26) | 25 (1.37) | 53 (7.31) |
| Smoking | 2,983 (11.84) | 1,898 (6.91) | 334 (3.16) | 37 (2.03) | 84 (11.59) |
| Lupus Nephritis (N, %) | 3,263 (12.95) | 7,309 (26.61) | 2,406 (22.78) | 582 (31.86) | 136 (18.76) |
| SLE Risk Adjustment index¥ (Mean, SD) | 1.55 (2.59) | 1.81 (2.67) | 1.44 (2.36) | 1.46 (2.38) | 1.69 (2.63) |
| Glucocorticoid Use (N, %) | |||||
| 0 to 5 mg/day | 21,686 (86.04) | 21,553 (78.46) | 8,289 (78.48) | 1,308 (71.59) | 623 (85.93) |
| >5 to 15 mg/day | 2,793 (11.08) | 4,517 (16.44) | 1,762 (16.68) | 411 (22.50) | 85 (11.72) |
| >15 mg/day | 725 (2.88) | 1,400 (5.10) | 511 (4.84) | 108 (5.91) | 17 (2.34) |
| Warfarin Use, Ever (N, %) | 1,915 (7.60) | 1,792 (6.52) | 702 (6.65) | 112 (6.13) | 43 (5.93) |
Baseline: 12 months prior to index date; CABG: coronary artery bypass graft, CVA: cerebrovascular accident, MI: myocardial infarction, PCI: percutaneous coronary intervention.
*
Comorbidities collected at any time up to and including index date. Cell sizes < 11 individuals suppressed in accordance with Federal reporting requirements;
¥
SLE specific index ranges from 0–46 (Reference: Ward MM, J Rheumatol. 2000; 27(6):1408–13)